Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Depreciation and Depletion (2022 - 2025)

Revolution Medicines (RVMD) has 4 years of Depreciation and Depletion data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 50.0% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $7.4 million, up 21.31%, while the annual FY2025 figure was $7.4 million, 19.35% up from the prior year.
  • Depreciation and Depletion reached $2.1 million in Q4 2025 per RVMD's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $2.1 million in Q4 2025 and bottomed at $900000.0 in Q1 2022.
  • Average Depreciation and Depletion over 4 years is $1.4 million, with a median of $1.3 million recorded in 2023.
  • The widest YoY moves for Depreciation and Depletion: up 50.0% in 2025, down 6.25% in 2025.
  • A 4-year view of Depreciation and Depletion shows it stood at $1.2 million in 2022, then grew by 8.33% to $1.3 million in 2023, then grew by 7.69% to $1.4 million in 2024, then surged by 50.0% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $2.1 million in Q4 2025, $2.0 million in Q3 2025, and $1.7 million in Q2 2025.